Will Rosellini co-founded CytoImmune in 2018 and became Chief Executive Officer of CytoImmune Biologics in November 2025. He led the in-license of City of Hope’s natural killer cell programs and their technology transfer through IND clearance. He built the company’s 38,000-square-foot Puerto Rico manufacturing facility, about 60 percent financed with non-dilutive tax credits. Earlier, he was founding CEO of MicroTransponder, whose Vivistim system became the first FDA-approved implantable device for chronic stroke rehabilitation. As CEO of Perimeter Medical Imaging, he secured two FDA clearances and took the company public on the TSX Venture Exchange. He founded Darrow Industries, a Puerto Rico neurotechnology venture studio, and has testified before Congress on the SBIR program. He holds a JD from Hofstra University, an MBA from the University of Texas at Dallas, and master’s degrees in neuroscience, accounting, regulatory science and computational biology.

Dr. Tania Rodriguez joined CytoImmune in 2021 and is the Director of Research and Process Development. She has over 17 years of experience in preclinical pharmacology and safety assessments of cell and gene therapies, process and assay development, and clinical biomarker strategies.

Prior to CytoImmune, Dr. Rodriguez was Associate Director and Principal Scientist at Invectys, USA. At Invectys, Dr. Rodriguez led the preclinical IND enabling studies plan of the company’s leading autologous Chimeric Antigen Receptor T cell (CAR-T) product, managed contract research and manufacturing organizations for Chemistry, Manufacturing, and Controls (CMC) activities, and was instrumental in the preparation of the pre-IND briefing package for the company’s first CAR-T product for the treatment of solid tumors (NCT05672459).

Prior to Invectys, Dr. Rodriguez was a lead scientist at Bellicum Pharmaceuticals, where she worked on preclinical assessments of the company’s T cell-based cell products including T-cells genetically modified to express CARs or T-cell receptors (TCRs) for the treatment of solid tumors and hematological malignancies. At Bellicum, she designed and conducted IND enabling vitro and in-vivo pharmacology, pharmacokinetics, and safety assessments leading to IND submission and clearance of the company’s first HER2-targeted dual switch autologous CAR-T product for the treatment of solid tumors (NCT04650451).

Dr. Rodriguez earned a PhD in Immunology & Experimental Therapeutics from the University of Texas Graduate School of Biomedical Sciences, Houston Texas. Her research focused on Major Histocompatibility Complex -I (MHC-I) molecules and dendritic cell-induced T-cell immunity against melanoma. After her PhD, Dr. Rodriguez joined the Cell and Gene Therapy Department at Baylor College of Medicine in Houston, Tx, as a post-doctoral fellow. Her research focused on the development of CAR-T cells for the treatment of glioblastoma.